Medicale Corp.
Medicale Corp.
No insider data available
Subscribe to unlock 17+ years of financial data
Subscribe to unlock 17+ years of data
Financial Statements
Values in Millions ($) | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 | 2023-03-31 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Financial statements beyond 3 years are for subscribers only. Unlock 17+ years of income statements, balance sheets, and cash flow statements Start 7-day free trial |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Cash | - | 0 | - | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||||
Assets Current | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||||
Cash And Cash Equivalents At Carrying Value | 0 | - | 0 | 0 | 0 | - | 0 | 0 | - | - | - | - | |||||
Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||||
Accounts Payable Current | - | - | - | - | 0 | - | - | - | - | - | - | - | |||||
Accrued Liabilities Current | - | - | - | - | 0 | - | - | - | - | - | - | - | |||||
Liabilities Current | |||||||||||||||||
Accounts Payable And Accrued Liabilities Current | 0 | 0 | 0 | 0 | 0 | 0 | - | - | - | - | - | - | |||||
Liabilities Current | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||||
Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - | - | |||||
Interest Payable Current | 0 | 0 | 0 | 0 | 0 | 0 | - | - | - | - | - | - | |||||
Accounts Payable And Other Accrued Liabilities Cur… | - | - | - | - | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||||
Liabilities Of Disposal Group Including Discontinu… | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||||
Convertible Long Term Notes Payable | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - | - | |||||
Liabilities Noncurrent | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - | - | |||||
Common Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||||
Additional Paid In Capital | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||||
Retained Earnings Accumulated Deficit | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | |||||
Liabilities And Stockholders Equity | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||||
Stockholders Equity | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | |||||
Common Stock Par Or Stated Value Per Share | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||||
Common Stock Shares Authorized | 75 | 75 | 75 | 75 | 75 | 75 | 75 | 75 | 75 | 75 | 75 | 75 | |||||
Common Stock Shares Issued | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | |||||
Shares Outstanding | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | |||||
Subscribe to unlock 17+ years of financial data, unlimited metrics, and saved tables
Subscribe to unlock 17+ years of data, unlimited metrics, and saved tables
Custom Table
Subscribe to unlock 17+ years of financial data, unlimited metrics, transformations, and saved visuals
Subscribe to unlock 17+ years of data, unlimited metrics, transformations, and saved visuals
Interactive Financial Visualizations
Subscribe to unlock 17+ years of financial data
Subscribe to unlock 17+ years of data
Earnings Market Reaction
| Fiscal Year | Q1 1 Month | Q1 2 Month | Q1 3 Month | Q2 1 Month | Q2 2 Month | Q2 3 Month | Q3 1 Month | Q3 2 Month | Q3 3 Month | Q4 1 Month | Q4 2 Month | Q4 3 Month |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 545.16% | 222.58% | 125.81% | - | - | - | - | - | - | - | - | - |
| 2025 | 314.95% | -14.67% | -6.77% | -7.32% | -1.22% | 4.62% | 0.00% | -11.06% | -7.17% | 19.23% | 0.00% | 284.62% |
| 2024 | 82.72% | 66.28% | 62.52% | 29.17% | 612.83% | 364.88% | -4.78% | -4.11% | -0.70% | 12.19% | 129.27% | -12.20% |
| 2023 | - | - | - | -10.00% | -30.00% | -55.00% | -24.42% | -47.67% | 539.53% | 71.10% | 13.19% | 47.53% |
Earnings Market Reaction data beyond 3 years is for subscribers only. Unlock the full earnings market reaction history Start 7-day free trial | ||||||||||||
Subscribe to unlock 17+ years of financial data and 90+ calculated metrics
Subscribe to unlock 17+ years of data and 90+ calculated metrics
Performance and Valuation Metrics
Rows marked with a lock icon are subscribers only — subscribe to unlock 90+ calculated metrics and 17+ years of history.
Metrics | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 | 2023-03-31 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Metric history beyond 3 years is for subscribers only. Unlock 17+ years of history across 90+ calculated metrics Start 7-day free trial |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Liquidity Ratios | |||||||||||||||||
| Current Ratio | - | - | - | - | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.00 | 0.01 | 0.01 | |||||
| Quick Ratio | - | - | - | - | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.00 | 0.01 | 0.01 | |||||
| Working Capital | - | - | - | - | -22.03K | -15.35K | -13.98K | -12.80K | -11.84K | -40.72K | -26.49K | -17.96K | |||||
Leverage & Debt | |||||||||||||||||
| Debt to Equity | -1.00 | -1.00 | -1.00 | -1.00 | -1.00 | -1.00 | -1.00 | -1.00 | -1.00 | -1.00 | -1.01 | -1.01 | |||||
| Debt Ratio | - | - | - | - | 728.13 | 623.22 | 517.05 | 451.26 | 378.53 | 257.10 | 167.62 | 113.93 | |||||
Efficiency & Turnover | |||||||||||||||||
| Asset Turnover TTM | - | - | - | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
Per Share Metrics | |||||||||||||||||
| Diluted EPS TTM | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 | |||||
| Free Cash Flow Per Share TTM | -0.00 | -0.00 | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 | -0.00 | -0.00 | -0.00 | |||||
| Dividend Per Share TTM | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
Growth Metrics | |||||||||||||||||
| Net Income Growth (1Y) | -46.46% | -29.31% | -14.75% | -2.49% | 15.36% | 56.75% | 49.09% | 51.25% | 33.92% | -19.99% | 16.22% | 9.09% | |||||
| EPS Growth (1Y) | -46.46% | -29.31% | -14.75% | -2.49% | 15.36% | 56.75% | 49.09% | 51.25% | 33.92% | -19.99% | 16.22% | 9.09% | |||||
Valuation Metrics | |||||||||||||||||
| P/E TTM | -23.67 | -21.72 | -20.25 | -20.38 | -20.24 | -28.47 | -28.77 | -14.35 | -18.43 | -70.14 | -285.95 | -333.88 | |||||
| P/B TTM | -4.85 | -6.38 | -7.41 | -8.60 | -9.73 | -16.75 | -19.48 | -10.75 | -14.79 | -63.97 | -402.22 | -659.39 | |||||
| Market Cap | 704.48K | 893.92K | 959.04K | 1.07M | 1.12M | 1.66M | 1.60M | 769.60K | 888.00K | 2.60M | 10.66M | 11.84M | |||||
| Enterprise Value | 817.65K | 1.00M | 1.06M | 1.16M | 1.22M | 1.74M | 1.67M | 828.23K | 936.03K | 2.60M | 10.66M | 11.84M | |||||
Calculated Values | |||||||||||||||||
| Free Cash Flow TTM | -19.75K | -23.01K | -32.06K | -39.33K | -65.88K | -83.59K | -80.32K | -79.27K | -53.60K | -25.74K | -17.05K | -11.75K | |||||
| Net Debt | 113.17K | 106.43K | 99.98K | 97.96K | 93.43K | 83.43K | 67.92K | 58.63K | 48.03K | -159.00 | -159.00 | -159.00 | |||||
Per-Share and Margin | |||||||||||||||||
| EPS TTM | |||||||||||||||||
| Adjusted EPS TTM | |||||||||||||||||
| Cash Flow Per Share TTM | |||||||||||||||||
| Pretax Margin TTM | |||||||||||||||||
| Stock Comp to Revenue TTM | |||||||||||||||||
Turnover Ratios and Averages | |||||||||||||||||
| Average Assets | |||||||||||||||||
| Average Equity | |||||||||||||||||
| Average Inventory | |||||||||||||||||
| Average Receivables | |||||||||||||||||
| Average Accounts Payables | |||||||||||||||||
| Inventory Turnover TTM | |||||||||||||||||
| Payables Turnover TTM | |||||||||||||||||
| Days Inventory Outstanding TTM | |||||||||||||||||
| Days Payables Outstanding TTM | |||||||||||||||||
| Cash Conversion Cycle TTM | |||||||||||||||||
| Working Capital to Revenue | |||||||||||||||||
| Deferred Revenue to Revenue | |||||||||||||||||
Growth Rates | |||||||||||||||||
| Total Assets Growth (1Y) | |||||||||||||||||
| Total Assets Growth (3Y) | |||||||||||||||||
| Total Assets Growth (5Y) | |||||||||||||||||
| Dividends Paid Growth (1Y) | |||||||||||||||||
| Dividends Paid Growth (3Y) | |||||||||||||||||
| Dividends Paid Growth (5Y) | |||||||||||||||||
| EPS Growth (3Y) | |||||||||||||||||
| EPS Growth (5Y) | |||||||||||||||||
| Net Income Growth (3Y) | |||||||||||||||||
| Net Income Growth (5Y) | |||||||||||||||||
| Net Profit Margin Growth (1Y) | |||||||||||||||||
| Net Profit Margin Growth (3Y) | |||||||||||||||||
| Net Profit Margin Growth (5Y) | |||||||||||||||||
| Net Revenue Growth (3Y) | |||||||||||||||||
| Net Revenue Growth (5Y) | |||||||||||||||||
| Deferred Revenue Growth (1Y) | |||||||||||||||||
| Retained Earnings Growth (1Y) | |||||||||||||||||
Credit, Liquidity, Returns, Payout | |||||||||||||||||
| Cash Ratio | |||||||||||||||||
| Net Working Capital | |||||||||||||||||
| Debt to EBITDA TTM | |||||||||||||||||
| Net Debt to EBITDA TTM | |||||||||||||||||
| Net Debt to Equity | |||||||||||||||||
| Altman A | |||||||||||||||||
| Altman B | |||||||||||||||||
| Altman C | |||||||||||||||||
| Altman D | |||||||||||||||||
| Altman E | |||||||||||||||||
| Altman Z-Score | |||||||||||||||||
| ROA TTM | |||||||||||||||||
| ROE TTM | |||||||||||||||||
| NOPAT TTM | |||||||||||||||||
| ROIC TTM | |||||||||||||||||
| Effective Tax Rate TTM | |||||||||||||||||
| Payout Ratio TTM | |||||||||||||||||
| Dilution Ratio | |||||||||||||||||
| Retained Earnings to Equity | |||||||||||||||||
| Treasury Stock to Equity | |||||||||||||||||
| Treasury Stock Change (1Y) | |||||||||||||||||
| Accrued to Current Liabilities | |||||||||||||||||
| NCAV | |||||||||||||||||
| NCAV Per Share TTM | |||||||||||||||||
Valuation Ratios | |||||||||||||||||
| P/CF TTM | |||||||||||||||||
| PEG Ratio | |||||||||||||||||
| Dividend Yield TTM | |||||||||||||||||
| Free Cash Flow Yield TTM | |||||||||||||||||
| EV EBITDA TTM | |||||||||||||||||
| EV EBIT TTM | |||||||||||||||||
| EV Revenue TTM | |||||||||||||||||
| EV FCF TTM | |||||||||||||||||
| Stock Compensation TTM | |||||||||||||||||
| Adjusted Net Income TTM | |||||||||||||||||
| Billings TTM | |||||||||||||||||
| Total Debt | |||||||||||||||||
| Invested Capital | |||||||||||||||||
Subscribe to unlock 17+ years of financial data
Subscribe to unlock 17+ years of data
Subscribe to unlock 17+ years of financial data
Subscribe to unlock 17+ years of data
Medicale Corp. (MCLE) — SEC Financial Statements & Analysis
Medicale Corp. (MCLE) is a services-health services company, incorporated in NV. Medicale Corp. trades on OTC as: MCLE. Based on its latest SEC filing (Form 10-Q, period ending 2025-12-31), Medicale Corp. reported a Debt-to-Equity ratio of -1.00x, a Price-to-Book (P/B) ratio of -4.85x (TTM), at a market cap of $704.48K. Figures below are sourced from SEC EDGAR, as-filed.
- Debt To Equity
- -1.00x
- P/B TTM
- -4.85x
- Market Cap
- $704.48K
Data as of 2025-12-31 · Source: SEC EDGAR
Frequently Asked Questions
What industry is Medicale Corp. in?
Medicale Corp. (MCLE) operates in the Services-Health Services industry.
What is MCLE's market cap?
Medicale Corp. (MCLE) has a market capitalization of $704.48K as of 2025-12-31.
What exchange does MCLE trade on?
Medicale Corp. (MCLE) trades on the OTC.
Where is Medicale Corp. incorporated?
Medicale Corp. is incorporated in NV.